$-0.40 EPS Expected for Rhythm Pharmaceuticals, Inc. (RYTM)

July 14, 2018 - By Richard Slagle

Analysts expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to report $-0.40 EPS on August, 13.After having $-0.60 EPS previously, Rhythm Pharmaceuticals, Inc.’s analysts see -33.33 % EPS growth. The stock decreased 2.21% or $0.73 during the last trading session, reaching $32.31. About 181,064 shares traded. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. The company has market cap of $1.10 billion. The Company’s lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alstr??m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. It currently has negative earnings. The firm was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.

More notable recent Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news were published by: Globenewswire.com which released: “Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating …” on June 18, 2018, also Globenewswire.com with their article: “Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating …” published on June 14, 2018, Benzinga.com published: “44 Stocks Moving In Thursday’s Mid-Day Session” on June 21, 2018. More interesting news about Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) were released by: Benzinga.com and their article: “38 Stocks Moving In Tuesday’s Mid-Day Session” published on June 19, 2018 as well as Globenewswire.com‘s news article titled: “Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering” with publication date: June 18, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.